ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 13, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 13, 2011
News
FDA Awards NIPTE Multimillion-Dollar Research Grant
By Erik Greb
Last week, FDA awarded a grant to the National Institute for Pharmaceutical Technology and Education to improve drug development and manufacturing. The grant could be worth as much as $35 million over the next five years.
AstraZeneca Plans $200-Million Manufacturing Plant in China
By Patricia Van Arnum
AstraZeneca is investing $200 million in a new manufacturing site in China. The new site represents AstraZeneca's largest investment in a single manufacturing facility globally.
FDA Outlines Strategy to Spur Biomedical Innovation
By Amy Ritter
In response to concerns about the sustainability of US drug-development efforts, FDA has released a report that outlines several steps that FDA will take to spur biomedical innovation and ensure that such innovation can be quickly translated into safe and effective therapies.
EMA Board Endorses 'Road Map to 2015'
By Rich Whitworth
After announcing the official appointment of Guido Rasi as new executive director, the EMA management board also endorsed the implementation plan for the agency's 'Road Map to 2015.'
DTC Advertising Ban Maintained in Europe
By Stephanie Sutton
The European Commission has adopted revised proposals clarifying the information that industry can supply to the public on prescription-only medicines, while maintaining a strict ban on direct-to-consumer advertising.
Week of Oct. 10, 2011: Vetter Opens New Facility in Chicago; Merck Announces Retirement of Chairman and Former CEO Richard T. Clark; and More
Vetter Opens New Facility in Chicago; Merck Announces Retirement of Chairman and Former CEO Richard T. Clark; and More.
Regulatory Roundup: FDA, CMS, Medicaid Launch Pilot Program to Conduct Parallel Reviews of Medical Devices
FDA, CMS, Medicaid Launch Pilot Program to Conduct Parallel Reviews of Medical Devices.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here